Ann: Investor Presentation, page-2

Solid presentation....

Confirms existing timelines and start dates for Phase 1 and gives some extra info on the multitude of Phase 2 studies Argenica will be looking to commence should Phase 1 prove the drug safe.

Having a drug which is potentially efficacious across, Stroke, Hypoxic ischemic encephalopathy (HIE,) Traumatic brain injury (TBI) & concussion and surgically induced stroke is a very very valuable asset.

A lot of people on here were upset about the recent capital raising. I agree it could have been done better although it is what it is and on days like these I'm especially glad they raised when they did, now the company can get on with what it's supposed to do with the peace of mind that they have adequate funds in the bank.